A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2013.11.007
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2014
Authors
Publisher
Elsevier BV